Jennifer Payne_ThPatient Voice est.1973

 Passionate*Potential*Policy Driven: PKU

Public Health Contributions at Your Service, PharmD, MAPP, BS

I'm not just writing policy, I'm shaping history on the future coverage of PKU treatment and leaving a footprint in the FDA regulatory hall of fame. For more on my published works, please visit my contributing author page at The Rare Disease Report

or see my commentary in response to NORD's 2015 State Progress Report Card, featuring medical foods policy.

Leading the education initiative


For over 15 years and still going strong!

Photo capture below with University of Maryland School of Medicine, helping to connect science to the world of clinical medicine, spotlight on PKU, educating the future doctors of America!



Click below for the expert facts:


Maternal PKU: Use my Contact Page, Join Me! for more on Preconception Tips, Team Management and Exclusive Interview with the Medical Experts

Forging Partnerships


A revolutionary milestone was reached at the federal policy level, much facilitated by the fostering of nongovernment partnerships and dedicated pharmacists. Giving recognition (below), President and CEO, Cambrooke Therapeutics, photo capture from the I CARE for RARE campaign, Baltimore VA Medical Center 2015.



What is a medical food? Click here


Guidance for Industry:   Click here



Seizing Opportunity


Real World Application of Strategic Capstone Report at focus: FDA medical foods regime and proposed regulatory policy initiative, photo capture: hand delivering a resource tool and statutory scheme to help FDA bring meaningful, positive outcomes and beneficial results through science-driven policy crafted by the expert, me!




 
My PKU Bio

Jennifer Payne has sustained exceptional performance in assuming great responsibility in the fields of health and medicine with an enhanced understanding of ethical leadership and government decision making.  Collateral assignments cross-cut civic, social and professional responsibilities, for which Ms. Payne has a long standing tenure as a licensed pharmacist, experienced in multiple practice settings and currently holds a primary tour of duty with the Outpatient Pharmacy Service under the VA Maryland Health Care System.  She received her BS from the University of Maryland at College Park 1995, PharmD from the University of Maryland at Baltimore 1999, and graduated in 2015 as a scholarship award recipient for a Master of Arts in Public Policy, New England College.  Pharmacy experiential learning rotations included work in drug evaluation and research at the FDA Office of Generic Drugs and drug information at the NIH Clinical Center in Bethesda, MD.  Her PKU advocacy efforts originated while still in attendance at pharmacy school.  It was at this time she began educating her peers after having been recruited by the University of Maryland School of Medicine genetics clinical correlates program.  She was the guest speaker and has participated in this educational program on an annual basis and continues to educate first year medical students today. She received special recognition in 2007 from the Vice Dean for Research and Academic Affairs at the University of Maryland School of Medicine and was awarded a Certificate of Appreciation for valuable and significant contributions to teaching, sharing her life story, and helping students to connect science to the world of clinical medicine. She maintains current knowledge on PKU science and research, has recently joined a distinguished list of individuals with outreach to over 80,000 clinicians, advocates and 22,000+ social media followers as contributing author for the Rare Disease Report, and is in pursuit of publication for her innovative ideas as author to statutory scheme and first-ever, proposed regulatory transformative initiative on FDA medical foods regime.   Her professional background compliments her personal goals and experiences,

which encompass numerous written avocations, testimony at FDA public meetings, as well as lobby efforts on Capitol Hill, teaching, and participation in various orphan disease summits, conferences, Congressional briefings and hearings, campaigns, and local and global observances of relevance to patients with rare disorders.  Current efforts are focused on championing the science of patient input, with focus on  federal, health care policy and stakeholder engagement that draws from an array of healthcare professionals and credentialed experts, advisory councils, federal bureaus, industry partners and accrediting agencies for health care institutions that are committed to safety and justice as a priority among federal operations and the health care industry as a whole for patients with rare disease.